CITY THERAPEUTICS, INC. - 8-K Filing

City Therapeutics doses first participant in Phase 1 clinical trial of CITY-RBP4 for Stargardt disease (Items: 7.01 Regulation FD Disclosure On November 10, 2026, City Therapeutics, Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CTY

Read the full article at SEC EDGAR

More Regulatory news